Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China
· Delayed Price · Currency is CNY 81.45
+0.74 (0.92%)
Apr 29, 2026, 4:00 PM EDT
SHE:301075 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2019 |
| Operating Revenue | 154.18 | 239.92 | 333.67 | 400.98 | 529.62 | Upgrade
|
| Other Revenue | - | 0.71 | 0.63 | 0.07 | - | Upgrade
|
| Revenue | 154.18 | 240.63 | 334.3 | 401.05 | 529.62 | Upgrade
|
| Revenue Growth (YoY) | -35.93% | -28.02% | -16.64% | -24.27% | 8.05% | Upgrade
|
| Cost of Revenue | 141.58 | 148.82 | 106.19 | 92.68 | 60.43 | Upgrade
|
| Gross Profit | 12.6 | 91.8 | 228.11 | 308.37 | 469.19 | Upgrade
|
| Selling, General & Admin | 79.99 | 135.04 | 202.13 | 272.76 | 374.79 | Upgrade
|
| Research & Development | 32.41 | 37 | 24 | 26.45 | 24.07 | Upgrade
|
| Other Operating Expenses | -5.29 | 1.93 | 3.71 | 4.64 | 6.59 | Upgrade
|
| Operating Expenses | 107.12 | 179.62 | 230.68 | 306.56 | 406.8 | Upgrade
|
| Operating Income | -94.52 | -87.81 | -2.57 | 1.81 | 62.38 | Upgrade
|
| Interest Expense | - | -7.9 | -3.11 | -1.36 | -1.18 | Upgrade
|
| Interest & Investment Income | 0.85 | 10.07 | 13.36 | 9.3 | 1.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -31.64 | -1.74 | 1.71 | -0.2 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | -125.3 | -87.39 | 9.39 | 9.55 | 62.3 | Upgrade
|
| Impairment of Goodwill | - | -0.23 | -0 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.04 | 0.54 | 0.07 | - | -0.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.11 | 0.04 | 0.08 | - | - | Upgrade
|
| Asset Writedown | -5.99 | -0.05 | -0.01 | -0.01 | -0 | Upgrade
|
| Other Unusual Items | - | 1.31 | 12.72 | 11.48 | 11.18 | Upgrade
|
| Pretax Income | -131.36 | -85.77 | 22.25 | 21.02 | 73.28 | Upgrade
|
| Income Tax Expense | 1.04 | -0.75 | 5.16 | 2.44 | 7.42 | Upgrade
|
| Earnings From Continuing Operations | -132.4 | -85.03 | 17.09 | 18.58 | 65.86 | Upgrade
|
| Minority Interest in Earnings | 30.23 | 22.36 | 1.76 | 1.92 | 2.65 | Upgrade
|
| Net Income | -102.17 | -62.67 | 18.85 | 20.5 | 68.51 | Upgrade
|
| Net Income to Common | -102.17 | -62.67 | 18.85 | 20.5 | 68.51 | Upgrade
|
| Net Income Growth | - | - | -8.05% | -70.07% | -25.53% | Upgrade
|
| Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 65 | Upgrade
|
| Shares Change (YoY) | -0.16% | 0.99% | -0.39% | 20.86% | 8.52% | Upgrade
|
| EPS (Basic) | -1.29 | -0.79 | 0.24 | 0.26 | 1.05 | Upgrade
|
| EPS (Diluted) | -1.29 | -0.79 | 0.24 | 0.26 | 1.05 | Upgrade
|
| EPS Growth | - | - | -7.69% | -75.24% | -31.37% | Upgrade
|
| Free Cash Flow | -147.65 | -108.09 | -11.28 | -31.6 | 42.8 | Upgrade
|
| Free Cash Flow Per Share | -1.86 | -1.36 | -0.14 | -0.40 | 0.66 | Upgrade
|
| Dividend Per Share | - | - | 0.125 | - | 0.625 | Upgrade
|
| Gross Margin | 8.17% | 38.15% | 68.24% | 76.89% | 88.59% | Upgrade
|
| Operating Margin | -61.30% | -36.49% | -0.77% | 0.45% | 11.78% | Upgrade
|
| Profit Margin | -66.27% | -26.04% | 5.64% | 5.11% | 12.93% | Upgrade
|
| Free Cash Flow Margin | -95.77% | -44.92% | -3.37% | -7.88% | 8.08% | Upgrade
|
| EBITDA | -45.36 | -61.1 | 15.76 | 16.44 | 76.07 | Upgrade
|
| EBITDA Margin | -29.42% | -25.39% | 4.71% | 4.10% | 14.36% | Upgrade
|
| D&A For EBITDA | 49.15 | 26.72 | 18.33 | 14.63 | 13.68 | Upgrade
|
| EBIT | -94.52 | -87.81 | -2.57 | 1.81 | 62.38 | Upgrade
|
| EBIT Margin | -61.30% | -36.49% | -0.77% | 0.45% | 11.78% | Upgrade
|
| Effective Tax Rate | - | - | 23.18% | 11.61% | 10.12% | Upgrade
|
| Revenue as Reported | - | 240.63 | 334.3 | 401.05 | 529.62 | Upgrade
|
| Advertising Expenses | - | 62.61 | 145.61 | 217.83 | 315.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.